Lenalidomide in relapsed refractory non-Hodgkin′s lymphoma: An Indian perspective | Zendy

KS Rachan Shetty | Zendy; KC Lakshmaiah | Zendy; Vishwanath Sathyanarayanan | Zendy; D. Lokanatha | Zendy; LinuJacob Abraham | Zendy; K. Govinda Babu | Zendy

AI Assistant Blog Pricing

Open Access

Lenalidomide in relapsed refractory non-Hodgkin′s lymphoma: An Indian perspective

Author(s) -

KS Rachan Shetty,

KC Lakshmaiah,

Vishwanath Sathyanarayanan,

D. Lokanatha,

LinuJacob Abraham,

K. Govinda Babu

Publication year - 2015

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 1998-4138

pISSN - 0973-1482

DOI - 10.4103/0973-1482.151418

Subject(s) - lenalidomide , medicine , mantle cell lymphoma , lymphoma , gastroenterology , refractory (planetary science) , follicular lymphoma , oncology , thalidomide , surgery , multiple myeloma , astrobiology , physics

Lenalidomide an immunomodulatory agent has shown activity in relapsed/refractory lymphoma. This study was conducted to evaluate its efficacy and optimal dose in Indian patients with relapsed/refractory lymphoma who were unable or unwilling to undergo autologous hematopoietic stem cell transplant.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog